ProfitQuotes.com
symbol lookup  commodity list
Bookmark This Page
Daily Dividend Report: PH, SYY, XOM, CVX, BAC

Fri, 26 Apr 16:24:29 GMT
Daily Dividend Report: PFE, SCHW, CI, MPC, AVY

Thu, 25 Apr 17:45:00 GMT
Portfolio Channel
Free Energy Dividend Stock Report
Free Dividend Report - Top Ranked Stocks
Free Dividend Paying Gold/Metals Stocks Report
Get a quote box (like the one below) for your site!
ProfitQuotes.com Commodities Quotes
commodity quotes list
energy quotes  gold quotes
uranium stocks  
solar power stocks

wind power stocks

Industry focus:

advertising stocks,
space stocks,
aerospace stock,
aerospace sector,
list of aerospace companies,
largest chemical companies,
chemical stock,
chemical news,
best agriculture stocks,
ag stocks,
chinese agriculture stocks,
top agriculture companies,
agriculture stocks,
agricultural stocks,
agricultural stock,
stocks agriculture,
agriculture markets,
agriculture index,
agriculture industries,
agricultural investment,
agriculture investment,
agricultural industry,
farm stock,
airline stock symbols,
airline stock prices,
airline stock,
airlines stock,
clothing stock,
fashion stocks,
publicly traded fashion companies,
clothing company stocks,
apparel stock,
apparel companies,
application software stocks,
asset management stocks,
auto stocks,
auto industry stocks,
chinese auto stocks,
auto stock prices,
automotive stock,
auto parts stocks,
community bank stocks,
regional bank stocks,
canadian bank stocks,
banking stock,
national bank stocks,
commercial bank stock,
banks stock,
bank stock quote,
bank stocks,
banking industry,
alcohol stocks,
beverage stock,
global wine stocks,
wine stocks,
liquor stock,
biotech stocks list,
biotechnology investing,
public biotech companies,
top biotech stocks,
nanotechnology stock,
largest biotech companies,
biotechnology stock,
biotech investing,
investing in biotech,
best biotech companies,
bio stocks,
biotech sector,
biotechnology investment,
biopharma companies,
new biotech companies,
biotech investment,
biotechnology industries,
nanotech stocks,
biotech stocks,
biotechnology articles,
biotechnology news,
business stocks,
service stocks,
chemical companies,
chemical industries,
chemical industry,
chemical company,
chemicals company,
cigarette stock,
cigarette company stocks,
cigarette stock symbols,
tobacco company stocks,
tobacco stock,
cigar stocks,
communications stocks,
communication stock,
computer peripherals companies,
computer peripherals,
computers stocks,
computer stock,
computer web,
internet stocks,
construction stocks,
machinery stocks,
builders stocks,
building stocks,
consumer goods stocks,
consumer services stocks,
consumer services companies,
lending stocks,
mortgage banking,
lending companies,
mortgage bankers,
loan services,
mortgage services,
mortgage bank,
loan bank,
defense stocks,
defensive stock,
department store stocks,
diagnostic company,
diagnostic companies,
pharmaceuticals stocks,
drug stocks,
drug company stocks,
pharma stock,
education stocks,
college stock,
electric utility stocks,
electric company stocks,
electric utilities stocks,
utility stocks,
utilities stocks,
power equipment companies,
electrical supply companies,
electronic stocks,
entertainment stock,
movie stocks,
movies companies,
movie company,
cefs,
open ended and closed ended mutual funds,
closed ended investment,
closed ended fund,
bonds fund,
closed end,
food stock,
game stock,
gambling stocks,
casino stocks,
gaming stocks list,
gaming stocks,
gas utility companies,
gas company stocks,
construction industries,
builders contractors,
construction services,
construction industry,
grocery store stocks,
supermarket stock,
drug store stocks,
home stocks,
furniture stock,
home improvement stocks,
medical company stocks,
top medical stocks,
medical stock,
hospital stock,
medical supply stocks,
medical technology stocks,
medical device stocks,
medical equipment stocks,
copper mining,
palladium mining stocks,
mining metals,
mining,
mining news,
gold exploration,
mining share price,
lithium mines,
mining industries,
international mining companies,
mining information,
molybdenum mining companies,
nickel mining companies,
metals and mining stocks,
gold and silver mining stocks,
copper mining companies,
rare earth mining companies,
rare metals stocks,
rare earth stocks,
metals stocks,
welding stock,
nonprecious metals,
non metallic mining,
office supplies companies,
office supply companies,
oil services stocks,
oil pipeline stocks,
gas pipeline stocks,
gas pipeline companies,
pipeline companies,
natural gas pipeline companies,
oil services companies,
oil field services,
oil service stocks,
natural gas pipelines,
oilfield service companies,
oil and gas pipeline companies,
oil gas pipeline,
oil exploration stocks,
oil exploration sector,
oil exploration companies,
oil drilling stocks,
oil drilling companies,
oil production companies,
china oil companies,
brazil oil companies,
china oil stocks,
brazil oil stocks,
oil companies,
oil stocks,
oil drilling,
oil exploration,
offshore oil drilling companies,
list of oil drilling companies,
oil and gas exploration,
oil and gas drilling,
oil and gas stocks,
oil and gas drilling companies,
oil refining companies,
oil marketing companies,
oil refining stocks,
oil refining sector,
oil refinery companies,
oil refinery stocks,
major oil companies,
oil sector,
oil refinery,
oil refinery company,
oil company,
oil marketing company,
oil refining company,
oil refining industry,
major oil companies list,
oil and gas companies,
crude oil stocks,
packaging companies,
container companies,
packaging stocks,
packaging sector,
container sector,
pulp stocks,
paper stocks,
timber stocks,
pulp companies,
paper companies,
timber companies,
timber trusts,
cardboard companies,
paper sector,
timber sector,
paper companies list,
silver mining companies,
gold mining companies,
gold mining sector,
precious metal stocks,
mining companies,
exploration sector,
mining sector,
exploration stocks,
mining stocks,
silver stocks,
gold stocks,
gold mining stocks,
silver mining stocks,
silver mining company,
canadian mining companies,
gold mining,
gold mining company,
mining company,
list of mining companies,
gold stocks list,
largest gold mining companies,
silver mining,
printing companies,
printing stocks,
printing sector,
newspaper stocks,
newspaper sector,
newspaper companies,
publishing stocks,
publishing sector,
publishing companies,
digital media companies,
digital media stocks,
digital media sector,
book publishing companies,
digital media company,
publishing company,
railroad stocks,
railroad sector,
railroad companies,
railroad company,
railroad investment,
major railroad companies,
real estate companies,
real estate stock,
real estate public companies,
real estate investing,
real estate investments,
real estate sector,
commercial real estate investing,
real estate investment firms,
real estate investing guide,
REITs,
real estate investment trust,
REIT sector,
REIT stocks,
REITs sector,
REITs stock,
public REITs,
real estate investment trusts,
real estate investment trust companies,
real estate investment trusts REITs,
real estate investment companies,
real estate investment company,
real estate investment trust REIT,
rubber stocks,
plastic stocks,
rubber companies,
plastic companies,
rubber sector,
plastic sector,
plastic manufacturing companies,
rubber company,
plastic company,
semiconductor stocks,
semiconductor investments,
semi stocks,
semiconductor companies,
semiconductor sector,
shipping stocks,
dry bulk stocks,
container stocks,
dry bulk shipping,
dry bulk shipping companies,
tanker stocks,
shipping companies,
shipping sector,
specialty retail,
retail stocks,
retail investing,
retail store stocks,
consumer stocks,
consumer investment,
retail companies,
retail sector,
sports stocks,
sports investing,
sporting goods stocks,
sports investments,
sporting goods companies,
sporting goods sector,
stock message boards,
television stocks,
television investment,
radio stocks,
radio invest,
media stocks,
media invest,
media investment,
media investing,
television companies,
television sector,
radio sector,
radio companies,
media companies,
media sector,
textile stocks,
apparel stocks,
textile investment,
textile companies,
textile sector,
apparel sector,
freight investment,
transportation investment,
truck investment ,
freight stocks,
transportation stocks,
trucking stocks,
trucking companies,
trucking sector,
waste management stocks,
waste stocks,
recycling stocks,
waste investment,
waste companies,
waste sector,
water stocks,
water utilities,
water investing,
water investment,
water companies,
water sector

Home Oil & Gas Electricity Metals Treasuries Stocks My Portfolios Forex
News - Full Story
 Related Quotes
 Biophytis SA - American Depositary Share  8.22   1.4831  15.29%
 Enter Symbols: 

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, publishes today its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes.

"In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development of our clinical programmes, while securing the company's financing until early 2025," states Stanislas Veillet, CEO of Biophytis. "We were able to confirm the therapeutic value of BIO101 (20-hydroxyecdysone), our lead drug candidate, in the treatment of patients suffering from severe forms of COVID-19, opening the door to wider use in viral Severe Acute Respiratory Infections (SARI). We have also obtained authorization to initiate a phase 3 SARA-31 trial in the United States and Belgium in sarcopenia, a disease that is still poorly understood but very common among the elderly and currently untreated. We are actively seeking global or regional pharmaceutical company partners to co-finance the phase 3 studies required to file a marketing authorization and to market BIO101 (20-hydroxyecdysone) in these two indications.Finally, we are starting a new phase 2 clinical development programme in obesity to assess the efficacy of BIO101 (20-hydroxyecdysone) in maintaining muscle function in obese patients treated with GLP-1 receptor agonists. We believe we can position ourselves as a key player in this fast-growing market, which is expected to reach over $100 billion by 2030 according to Goldman Sachs."

2023 Highlights and outlook for 2024

SARA programme

  • Positive advice obtained from the Belgian authorities and the FDA in the second half of 2023 to start SARA-31, the first phase 3 study ever launched in sarcopenia, based on the positive results obtained in the SARA-INT phase 2b study.
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

OBA programme

  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • 2024: Phase 2 OBA study to start mid-2024, subject to regulatory approvals and financial resources. First patients enrolled in H2 2024.

COVA programme

  • Final results of the phase 2-3 COVA clinical trial: the study met its primary objective, with a significant 44% (p=0.043) reduction in the risk of respiratory failure or early death in patients hospitalised with severe COVID-19. In addition, BIO101 (20-hydroxyecdysone) has a very good safety profile, with a lower proportion of patients experiencing adverse events compared with placebo (57% vs. 64%).
  • Implementation of regulatory procedures to assess the conditions for market access based on the results of the COVA study, and preparation for the design of a second confirmatory phase 3 trial.
  • Setting up industrial partnerships with the Seqens and Skyepharma groups, with a view to commercial-scale production of the BIO101 (20-hydroxyecdysone) drug candidate.
  • Partnership with the University of Li ge to study the value of BIO101 (20-hydroxyecdysone) in the treatment of respiratory failure caused by the influenza virus. BIO101 (20-hydroxyecdysone) could treat severe forms of the main viral severe acute respiratory infections (SARI) and significantly expand the product's target market.
  • 2024: Reactivation of an early access programme in Brazil and extension to Europe. This strategy may be rolled out subject to regulatory approvals, particularly in Brazil, where early access authorization is currently being reactivated.

MYODA programme

  • 2024: presentation of the results obtained with BIO101 (20-hydroxyecdysone) in Duchenne Muscular Dystrophy at the Muscular Distrophy Association (MDA) Conference in Dallas, Texas, from March 19 to 22, 2024. On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.

Key 2023 financial figures

The figures presented below and in appendices have been prepared in accordance with IFRS Accounting Standards and were approved by the Board of Directors on 8 April 2024.

Cash position

Consolidated cash and cash equivalents were 5.6 million at December 31, 2023, compared with 11.1 million at December 31, 2022, a net decrease of 5.5 million. Cash used in operating activities amounted to 12.6 million, and was partially offset by new cash injections, in the form of fundraising or convertible bond issues, totalling almost 8 million.

Taking into account the possibility of additional drawings on its ORNANE financing line, and on the basis of its financing plan, at the date of filing of the annual report on Form 20-F and the Annual Financial Report, the Company's available cash and cash equivalents should not be sufficient to support its operating plan for at least the next 12 months. There is therefore significant doubt about the Company's ability to continue its business activities.

On the basis of its current operations and its plans and assumptions, the Company believes that it will be able to finance its activities until the first quarter of 2025.

Consolidated results


2022 2023
(Amounts in thousands of euros, except share and per share data)
12 months 12 months
Revenues
- -
Cost of sales
- -
Gross margin
- -

Research and development expenses, net
(16,034) (8,845)
General and administrative expenses
(7,237) (5,488)
Operating loss
(23,272) (14,333)

Financial expenses
(2,564) (1,633)
Financial income
983 269
Change in fair value of derivative liabilities and convertible bonds
637 (1,330)
Net financial expense
(944) (2,694)

Loss before taxes
(24,216) (17,026)

Income taxes benefit
- -
Net loss
(24,216) (17,026)

Operating expenses have fallen sharply between 2022 and 2023, as a result of:

  • A significant reduction in R&D expenditure linked to the completion of clinical trials for the COVA and SARA programmes. Residual costs relating to clinical development were booked in 2023, but the bulk of R&D expenditure concerned pre-clinical work and operations relating to the production of BIO101.
  • The fall in staff costs was mainly due to the valuation of instruments giving access to capital, while the Company's headcount remained stable.

The change in the financial result is essentially due to the revaluation of financial debts in accordance with IFRS 9.

As a result of the above, the annual loss has been significantly reduced, from 24.2 million at December 31, 2022 to 17 million at December 31, 2023.

****

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information, visit www.biophytis.com

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook,""believes,""expects,""potential,""continues,""may,""will,""should,""could,""seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of thesewords or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information,future developments or otherwise, except as required by law.

Biophytis contacts

Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com

Media
Antoine Denry:antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50

Consolidation statement of financial situation

(amounts in thousands of euros)
2022 2023
ASSETS


Patents and software
2,655 2,637
Property, plant and equipment
584 315
Other non-current financial assets
173 158
Total non-current assets
3,411 3,110

Other receivables and prepaid expenses
6,934 2,916
Other current financial assets
590 368
Cash and cash equivalents
11,053 5,567
Total current assets
18,576 8,850

TOTAL ASSETS
21,987 11,960


LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Shareholder' equity
Share capital
47,660 2,081
Premiums related to the share capital
(1,588) 13,483
Treasury shares
(21) (12)
Foreign currency translation adjustment
(25) (25)
Reserves - attributable to the owners of the parent
(23,689) (2,357)
Net loss - attributable to the owners of the parent
(24,216) (17,026)
Shareholder equity - attributable to the owners of the parent
(1,879) (3,857)
Non-controlling interests
(32) (32)
Total shareholder equity (deficit)
(1,911) (3,889)

Liabilities
Employee benefit obligations
183 237
Non-current financial liabilities
4,367 3,247
Non-current derivative financial instruments
- -
Total non-current liabilities
4,551 3,484

Current financial liabilities
10,213 5,023
Provisions
75 223
Trade payable
6,940 5,392
Tax and social liabilities
1,780 1,348
Current derivative financial liabilities
13 1
Other creditors and miscellaneous liabilities
328 378
Total current liabilities
19,348 12,365

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
21,987 11,960

Consolidated financial of profit or loss


2022 2023
(Amounts in thousands of euros, except share and per share data)
12 months 12 months
Revenues
- -
Cost of sales
- -
Gross margin
- -

Research and development expenses, net
(16,034) (8,845)
General and administrative expenses
(7,237) (5,488)
Operating loss
(23,272) (14,333)

Financial expenses
(2,564) (1,633)
Financial income
983 269
Change in fair value of derivative liabilities and convertible bonds
637 (1,330)
Net financial expense
(944) (2,694)

Loss before taxes
(24,216) (17,026)

Income taxes benefit
- -
Net loss
(24,216) (17,026)

Attributable to the owners of the parent
(24,216) (17,026)
Non-controlling interests
- -

Basic and diluted weighted average number of shares outstanding
174,839,276 543,074,353
Basic loss per share ( /share)
(0.14) (0.03)
Diluted loss per share ( /share)
(0.14) (0.03)

2022 2023
(amounts in thousands of euros)
12 months 12 months
Net loss for the year
(24,216) (17,026)
Items that will not be reclassified to profit or loss
Actuarial gains and losses
80 1
Items that will be reclassified to profit or loss
Foreign currency translation adjustment
48 (1)
Other comprehensive income items
128 1

Total other comprehensive profit or loss
(24,089) (17,026)

(17,026)
Attributable to the owners of the parent
(24,089) (17,026)
Non-controlling interests
- -

Statement of consolidated cash flows


2022 2023
(amounts in thousands of euros)
12 months 12 months
Cash flow used in operating activities


Net loss
(24,216) (17,026)
Amortization and depreciation of intangible and tangible assets
484 803
Additions of provisions, net of reversals
(89) (72)
Expenses associated with share-based payments
5,567 812
Financial interest
1,853 1,022
Amortization of the day one Loss
- -
Change in fair value of financial instruments
(637) 1,330
Interests on investment accounts
(4) -
Net financial indemnities Negma
(1,000) -
Unwinding of conditional advances and other financial expenses
22 12
Amortized cost of non-convertible bonds and debt component of the convertible notes
364 272
Cash flow used in operating activities before changes in working capital
(17,652) (12,847)
(-) Change in working capital (net of depreciation of trade receivables and inventories)
(1,335) (26)
(Increase) decrease in Other non-current financial assets
- 14
(Increase) decrease in other receivables
(398) 1,670
Increase (decrease) in trade accounts payable
(665) (1,328)
Increase (decrease) in tax and social security liabilities
(219) (432)
Increase (decrease) in other creditors and accrued liabilities
(53) 50

Cash flow used in operating activities
(18,988) (12,873)

Cash flow used in investment operations
Acquisition of intangible and tangible assets
(141) (220)
Purchase of term deposits classified as other current financial assets
110 -
Decrease (increase) in short term deposits accounts
14 590
Cash flow used in investment operations
(17) 370

Cash flow from/used in to financing operations
Proceeds from share capital increase
- 5,541
Costs paid in relation to equity transactions
- (1,303)
Net financial indemnity received from/ (paid to) Negma
1,000 -
Exercise of warrants (BSA) and founders' warrants (BSPCE)
6 2,146
Proceeds from research tax credit prefinancing, net of guarantee deposit
1,834 1,098
Reimbursement of the prefinanced CIR receivables, net of guarantee deposit
(3,450) -
Proceeds from conditional advances
4 -
Repayment of conditional advances
(224) (220)
Proceeds from subsidies
204 -
Financial interest paid
(662) (460)
Proceeds from the issuance of convertible notes and non-convertible bonds
9,510 1,890
Repayment non-convertible bonds
(1,844) (1,262)
Costs incurred in relation to the issuance of convertible notes and non-convertible bonds
- (121)
Repayment of lease obligations
(244) (283)
Cash flow used in financing operations
6,134 7,027

Net effect of exchange rate changes on cash and cash equivalents
(3) (9)

Increase (decrease) in cash and cash equivalents
(12,873) (5,485)

Cash and cash equivalents at the beginning of the period
23,926 11,053
Cash and cash equivalents at the end of the period
11,053 5,568

SOURCE: Biophytis



View the original press release on accesswire.com

<  back


TickerTech.com Private-label branded pages powered by TickerTech.com. Copyright © 2024 Ticker Technologies, All Rights Reserved. Quote data is at least 20 minutes delayed. NYMEX/COMEX data is at least 30 minutes delayed. Please read other important disclaimer information.
"The only source from which an entrepreneurs profits stem is his ability to anticipate better than other people the future demand of the consumers." - Ludwig von Mises
Google
 

© Ticker Technologies, all rights reserved. Profitquotes.com is wholly owned by Ticker Technologies and serves to demonstrate the company's products to prospective clients. All quotes are in US Eastern Time (EST) and delayed at least 15 minutes. NYMEX/COMEX data delayed at least 30 minutes. Data is presented for informational purposes only and not intended for investment purposes. Nothing on this site should be considered advice, opinions, recommendations, or endorsements from ProfitQuotes.com or TTI Group. Full Disclaimer.